Phase 2 multi-center, open-label study to evaluate the efficacy and safety of patient-specific immunotherapy, recombinant idiotype conjugated to KLH (Id-KLH) and administered with GM-CSF, in patients with follicular non-Hodgkin's lymphoma following primary treatment with rituximab and chemotherapy (R-Chemo)

Trial Profile

Phase 2 multi-center, open-label study to evaluate the efficacy and safety of patient-specific immunotherapy, recombinant idiotype conjugated to KLH (Id-KLH) and administered with GM-CSF, in patients with follicular non-Hodgkin's lymphoma following primary treatment with rituximab and chemotherapy (R-Chemo)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2008

At a glance

  • Drugs GTOP 99; Sargramostim
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Sponsors Genitope Corporation
  • Most Recent Events

    • 17 Mar 2008 Status changed from recruiting to discontinued as reported by ClinicalTrial.gov
    • 30 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top